国药现代：富马酸喹硫平缓释片和曲氟尿苷替匹嘧啶片获药品注册证书

Core Insights - The company announced that its wholly-owned subsidiary, China National Pharmaceutical Group Industrial Co., Ltd., and its controlling subsidiary, China National Pharmaceutical Yixin Pharmaceutical Co., Ltd., have obtained drug registration certificates for two medications: Fumaric Acid Quetiapine Sustained-Release Tablets and Capecitabine Tablets [1] Group 1: Drug Registration and Sales - Fumaric Acid Quetiapine Sustained-Release Tablets are primarily used for the treatment of schizophrenia and bipolar disorder, with sales in public hospitals and urban pharmacies reaching 445 million yuan in 2023 [1] - Capecitabine Tablets are indicated for metastatic colorectal cancer, achieving sales of 164 million yuan in public hospitals and urban pharmacies in 2023 [1] Group 2: R&D Investment - China National Pharmaceutical Group Industrial Co., Ltd. and China National Pharmaceutical Yixin Pharmaceutical Co., Ltd. have made cumulative R&D investments of approximately 16.32 million yuan and 27.50 million yuan, respectively [1]